Sunday, July 13, 2025
15.5 C
London
HomeFinTechStarpharma: Advances progress for COVID-19 nasal spray

Starpharma: Advances progress for COVID-19 nasal spray

Date:

Ageras Makes 8th Acquisition with Payroll Company Employes to Expand Fintech Services

Ageras strengthens its fintech ecosystem by acquiring Employes, enhancing...

UK Chancellor Halts ISA Reductions After Backlash from Investors

Following strong criticism, the UK Chancellor has suspended planned...

UK Chancellor Reverses ISAs Reductions After Public Backlash

A bold move by the Chancellor to protect savers...
  • During the September quarter, Starpharma (SPL) achieved several milestones with its SPL7013 COVID-19 nasal spray
  • Additionally, the pharmaceutical company made progress with its Dendrimer Enhanced Product (DEP) candidates and VivaGel BV
  • The DEP candidates used to treat varying tumours and all are progressing well with phase 2 trials
  • The product launched in the Nordic region and regulatory approvals were received for countries in Africa and the Middle East
  • As of September 30, Starpharma had a cash balance of $24.9M, a decrease from the $36.8M in the prior corresponding period
  • Net operating cash outflows were $4.7 million, with the majority going towards research and development, and staff costs

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories